Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Tranquis Therapeutics.

    Client Virtual Booth

    TRANQUIS THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Tranquis Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    951 Mariners Island Blvd Suite 300 San Mateo, CA 94404
    Telephone
    Telephone
    +1 650 684-8950
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.tranquis.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/tranquis/
    Twitter
    Twitter
    https://twitter.com/tranquistx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022

    Details:

    TQS-168 is a PGC-1a-enhancing small molecule in development for the treatment of neurodegenerative, metabolic, and aging-related diseases in which PGC-1a modulation plays a critical role.


    Lead Product(s): TQS-168

    Therapeutic Area: Neurology Product Name: TQS-168

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 29, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Tranquis Therapeutics Granted FDA Orphan Drug Designation for TQS-168 for the Treatment of Amyotrophic Lateral Sclerosis

    Details:

    TQS-168, a small molecule modulator of PGC-1a, for the treatment of amyotrophic lateral sclerosis (ALS). TQS-168 showed survival and functional benefits in various animal models of neurodegenerative disease, including ALS and Parkinson’s disease.


    Lead Product(s): TQS-168

    Therapeutic Area: Neurology Product Name: TQS-168

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 21, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Tranquis Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of TQS-168

    Details:

    The data from our Phase 1 study of TQS-168, a small molecule modulator of PGC-1a demonstrate that target plasma exposures can be achieved at dose levels that are well tolerated.


    Lead Product(s): TQS-168

    Therapeutic Area: Neurology Product Name: TQS-168

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 02, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Tranquis Therapeutics Launches with $30 Million Series A Funding to Advance Novel Immuno-Neurology to Treating Neurodegenerative Diseases

    Details:

    The financing will support company's novel platform based on groundbreaking research from the laboratory of Professor Edgar Engleman, MD, at Stanford University indicating that myeloid immune cell dysfunction underlies a variety of nervous system disorders.


    Lead Product(s): TQS-168

    Therapeutic Area: Neurology Product Name: TQS-168

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Remiges Ventures

    Deal Size: $30.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing July 09, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search